dr. goy on preliminary data with ibrutinib/venetoclax in relapsed/refractory mcl
Published 4 years ago • 132 plays • Length 1:24Download video MP4
Download video MP3
Similar videos
-
1:09
dr. goy discusses ibrutinib with venetoclax in mcl
-
1:05
dr. goy on combinations with novel agents in relapsed/refractory mcl
-
1:06
dr. goy on efficacy with ibrutinib in mcl
-
0:47
venetoclax plus ibrutinib combo shows potential in relapsed/refractory mcl
-
1:25
dr. lee on early efficacy data with cirmtuzumab/ibrutinib in relapsed/refractory mcl
-
0:46
dr. goy compares acalabrutinib with ibrutinib in mcl
-
1:06
dr. goy on promising data with acalabrutinib in mcl
-
1:00
dr. goy on acalabrutinib versus ibrutinib in mcl
-
1:02
dr. goy on the progression of mcl treatment
-
1:20
dr. goy the evolution of treatment in relapsed/refractory mcl
-
1:27
dr. rule on the combination of venetoclax and ibrutinib in mcl
-
1:08
dr. goy on advancements in relapse/refractory mantle cell lymphoma
-
2:00
preliminary results of the aim trial of ibrutinib and venetoclax in mantle cell lymphoma
-
1:36
dr. rule on long-term follow-up of ibrutinib monotherapy in relapsed/refractory mcl
-
3:06
durable responses to ibrutinib and venetoclax in r/r mcl: 3-year aim update
-
7:11
selection of a btk inhibitor in relapsed/refractory mcl
-
1:33
dr. jacobs on the efficacy of ibrutinib and acalabrutinib in patients with mcl
-
1:27
dr. ritchie on immunological response to venetoclax/ibrutinib in r/r mcl
-
1:13
dr. goy on research efforts with btk inhibitors in mcl